Successful IL-17A inhibitor cycling in psoriatic arthritis patient: a case report and a literature review (CROSBI ID 306161)
Prilog u časopisu | stručni rad | međunarodna recenzija
Podaci o odgovornosti
Barešić, Marko ; Smiljanić Tomičević, Ljiljana ; Anić, Branimir ; Mayer, Miroslav
engleski
Successful IL-17A inhibitor cycling in psoriatic arthritis patient: a case report and a literature review
Psoriatic arthritis is an inflammatory arthritis with heterogeneous disease presentation. The most affected clinical domain of the disease determines the therapeutic approach. We report the case of a 34-year-old man with all six crucial domains of psoriatic arthritis (psoriasis, peripheral arthritis, axial skeletal manifestations, dactylitis, nail changes, and enthesitis) treated unsuccessfully with conventional synthetic DMARDs, NSAID’s, and steroids as well as topical treatment and phototherapy. With golimumab as the first line of bDMARD partial remission was achieved. After 24 months the treatment was switched to secukinumab due to secondary inefficacy. The psoriasis and psoriatic arthritis relapsed after 21 months of treatment with secukinumab. The patient was cycled to ixekizumab with an excellent result. IL-17A inhibitor cycling may be a successful treatment option in some difficult to treat psoriatic arthritis patients.
Psoriatic arthritis ; Interleukin-17A inhibitor ; Cycling ; Secukinumab ; Ixekizumab
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
42 (2)
2022.
365-370
objavljeno
0172-8172
1437-160X
10.1007/s00296-021-05065-1
Povezanost rada
Farmacija, Kliničke medicinske znanosti